A detailed history of Baillie Gifford & CO transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 357,698 shares of BEAM stock, worth $8.76 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
357,698
Previous 623,640 42.64%
Holding current value
$8.76 Million
Previous $14.6 Million 40.02%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

SELL
$22.57 - $33.14 $6 Million - $8.81 Million
-265,942 Reduced 42.64%
357,698 $8.76 Million
Q2 2024

Jul 25, 2024

SELL
$21.22 - $32.66 $2.73 Million - $4.21 Million
-128,754 Reduced 17.11%
623,640 $14.6 Million
Q1 2024

May 01, 2024

SELL
$23.46 - $45.07 $275,162 - $528,626
-11,729 Reduced 1.53%
752,394 $24.9 Million
Q4 2023

Jan 26, 2024

SELL
$17.69 - $30.76 $1.97 Million - $3.43 Million
-111,624 Reduced 12.75%
764,123 $20.8 Million
Q3 2023

Nov 13, 2023

BUY
$23.01 - $32.46 $8.1 Million - $11.4 Million
352,014 Added 67.21%
875,747 $21.1 Million
Q2 2023

Jul 28, 2023

BUY
$29.32 - $35.99 $2.08 Million - $2.55 Million
70,972 Added 15.68%
523,733 $16.7 Million
Q1 2023

May 03, 2023

SELL
$30.15 - $48.79 $62,320 - $100,848
-2,067 Reduced 0.45%
452,761 $13.9 Million
Q4 2022

Jan 24, 2023

BUY
$36.73 - $51.6 $2.56 Million - $3.59 Million
69,610 Added 18.07%
454,828 $17.8 Million
Q3 2022

Oct 27, 2022

BUY
$39.79 - $70.31 $14.9 Million - $26.3 Million
374,545 Added 3509.28%
385,218 $18.4 Million
Q4 2021

Jan 20, 2022

SELL
$68.02 - $99.06 $1,836 - $2,674
-27 Reduced 0.25%
10,673 $851,000
Q3 2021

Oct 19, 2021

BUY
$84.37 - $133.6 $861,670 - $1.36 Million
10,213 Added 2097.13%
10,700 $931,000
Q2 2021

Aug 02, 2021

SELL
$64.12 - $128.71 $2,051 - $4,118
-32 Reduced 6.17%
487 $63,000
Q1 2021

May 06, 2021

BUY
$71.28 - $120.75 $1,710 - $2,898
24 Added 4.85%
519 $42,000
Q4 2020

Feb 10, 2021

BUY
$22.24 - $95.63 $11,008 - $47,336
495 New
495 $40,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.72B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.